shares of adamis pharmaceuticals corp admp soared 204 on massive volume toward an eightmonth high in premarket trading monday after the biopharmaceutical company said zimhi its highdose naloxone injection for the treatment for opioid overdose has been approved by the food and drug administration trading volume spiked to 328 million shares enough to make the stock the most actively traded ahead of the open and compared with the fullday average of about 20 million shares we are very excited by this approval and are working with our commercial partner us worldmeds to make this muchneeded lifesaving product readily available to the market said adamis chief executive dennis carlo zimhi provides the highest systemic levels of naloxone compared to any of the nasal or intramuscular products currently available the stock has soared 1329 year to date through friday while the ishares biotechnology etf ibb has tacked on 37 and the sp 500 spx has gained 190